de Leij L, Poppema S, Nulend J K, Ter Haar J G, Schwander E, The T H
Eur J Cancer Clin Oncol. 1984 Jan;20(1):123-8. doi: 10.1016/0277-5379(84)90043-9.
To prepare monoclonal antibodies against small cell carcinoma of the lung (SCCL), we have used an SCCL-derived cell line as immunogen. A first screening of hybridoma supernatants was performed on frozen tissue sections of a biopsy with histologically proven SCCL involvement. Screening on tissue sections is a valuable technique, especially for the isolation of monoclonal antibodies directed against tumor antigens. A drawback of this procedure is that it is laborious. To circumvent this, we have reduced the number of supernatants to be screened by increasing the number of seeded hybridomas per well. Although this resulted in the growth of 5-20 hybridomas per well, among which there was always at least one that secreted antibodies against 'common antigens', clones that secreted specific antibodies could still be revealed by testing supernatants which were preabsorbed with thrombocytes. This has resulted in the isolation of 7 monoclonal antibodies directed against SCCL associated antigens.
为制备抗肺小细胞癌(SCCL)的单克隆抗体,我们使用了一种源自SCCL的细胞系作为免疫原。首次对杂交瘤上清液进行筛选是在经组织学证实有SCCL累及的活检冷冻组织切片上进行的。在组织切片上进行筛选是一项有价值的技术,尤其对于分离针对肿瘤抗原的单克隆抗体而言。该方法的一个缺点是操作繁琐。为避免这一问题,我们通过增加每孔接种的杂交瘤数量来减少需筛选的上清液数量。尽管这使得每孔有5 - 20个杂交瘤生长,其中总是至少有一个分泌针对“共同抗原”的抗体,但通过检测用血小板预先吸附过的上清液,仍可发现分泌特异性抗体的克隆。这导致分离出了7种针对SCCL相关抗原的单克隆抗体。